Genitourinary oncologist, Dana-Farber Cancer Institute
Appears in 1 story
Leading investigator in adjuvant kidney cancer trials
Surgery removes the tumor. For many high-risk kidney cancer patients, it doesn't end the disease. On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved pairing belzutifan with the immunotherapy pembrolizumab to keep these patients cancer-free for longer after their kidney is removed.
Updated Jun 12
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
